Radiosynthesis of no-carrier-added meta-[(124)I]iodobenzylguanidine for PET imaging of metastatic neuroblastoma

Meta-iodobenzylguanidine (mIBG) has been radiolabelled at the no-carrier-added level with [(124)I] for a proof of concept study to assess the diagnostic accuracy of [(124)I]mIBG PET/CT in detecting metastatic deposits in patients diagnosed with metastatic neuroblastoma. Radiolabelling of mIBG was ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Green, Michael, Lowe, Jonathan, Kadirvel, Manikandan, McMahon, Adam, Westwood, Nigel, Chua, Sue, Brown, Gavin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5219010/
https://www.ncbi.nlm.nih.gov/pubmed/28111488
http://dx.doi.org/10.1007/s10967-016-5073-1
Descripción
Sumario:Meta-iodobenzylguanidine (mIBG) has been radiolabelled at the no-carrier-added level with [(124)I] for a proof of concept study to assess the diagnostic accuracy of [(124)I]mIBG PET/CT in detecting metastatic deposits in patients diagnosed with metastatic neuroblastoma. Radiolabelling of mIBG was achieved via the iododesilylation reaction between [(124)I]sodium iodide and meta-trimethylsilylbenzylguanidine. [(124)I]mIBG was produced in 62–70 % radioiodide incorporation yield from [(124)I]sodium iodide. The average amount of formulated [(124)I]mIBG was 359 MBq (range 344–389 MBq) with an average specific radioactivity of 4.1 TBq μmol(−1) (range 1.8–5.9 TBq μmol(−1)) at end of synthesis.

Ejemplares similares